GSK plc's Jemperli (dostarlimab) trial reported unprecedented results with 100% of patients showing no disease in a cohort of 42 with dMMR rectal cancer, as announced on June 3, 2024. This data was presented at the ASCO Annual Meeting; the trial aims to offer new treatment alternatives to improve patient quality of life.